RBC Capital Maintains Sector Perform on CRISPR Therapeutics, Raises Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained a 'Sector Perform' rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $50 to $57.
December 11, 2023 | 4:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Luca Issi maintains a 'Sector Perform' rating on CRISPR Therapeutics and raises the price target from $50 to $57.
The increase in price target by RBC Capital suggests a positive outlook on CRISPR Therapeutics' stock, which could lead to a short-term increase in its stock price. The 'Sector Perform' rating indicates that the analyst believes the company will perform in line with the sector, but the raised target implies a belief in potential upside.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100